Xiang Hongyu, Liu Yinhua
Breast Disease Center, Peking University First Hospital, Beijing, China.
Transl Breast Cancer Res. 2023 Jan 31;4:2. doi: 10.21037/tbcr-22-50. eCollection 2023.
The Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2021 was published nearly one year ago. The new guideline was revised based on comprehensive feedback of the previous publication. The aim is to provide a better reference suitable for Chinese breast surgeons.
Referred to GRADE (Grading of Recommendations Assessment, Development and Evaluation) system, evidences accepted by the Guideline were classified into four categories: I, II, III and IV, which reflected the reliability of the evidences quantitatively. The guideline also comprehensively considered the accessibility of the guideline in clinical practice in China and gave recommendations with different strengths.
The guideline emphasized the basic idea that a curative surgical approach falls under the category of radical tumor surgery. Six chapters, including "Diagnosis and treatment of patients with invasive breast cancer", "Sentinel lymph node biopsy in patients with early-stage breast cancer", "Breast-conserving surgery in patients with early-stage breast cancer", "Modified radical mastectomy of breast cancer", "Central venous access for the systemic treatment of breast cancer", and "Breast cancer in pregnancy and postpartum breast cancer" were revised.
Compared with the 2021 edition, the new guideline has been revised in six chapters based on the latest research evidence and clinical needs.
《中国乳腺外科手术学组(CSBrS)2021版实践指南》已于近一年前发布。新指南是在对先前版本的全面反馈基础上修订而成。目的是提供一个更适合中国乳腺外科医生的参考。
参照推荐分级的评估、制定与评价(GRADE)系统,指南所采纳的证据分为I、II、III和IV四类,定量反映证据的可靠性。该指南还全面考虑了其在中国临床实践中的可及性,并给出了不同强度的推荐。
该指南强调了根治性手术方法属于根治性肿瘤手术范畴这一基本理念。对包括“浸润性乳腺癌患者的诊断与治疗”“早期乳腺癌患者的前哨淋巴结活检”“早期乳腺癌患者的保乳手术”“乳腺癌改良根治术”“乳腺癌全身治疗的中心静脉通路”以及“妊娠合并乳腺癌和产后乳腺癌”在内的六章内容进行了修订。
与2021版相比,新指南基于最新研究证据和临床需求在六章内容上进行了修订。